Histone Deacetylase Inhibitors and Cholesterol Metabolism
Author Information
Author(s): Chittur Sridar V, Sangster-Guity Niquiche, McCormick Paulette J
Primary Institution: Center for Functional Genomics, University at Albany, State University of New York
Hypothesis
This study explores the effects of histone deacetylase inhibitors on cholesterol metabolism.
Conclusion
The study suggests that histone deacetylase inhibitors like TSA may help control cholesterol levels by downregulating key genes in cholesterol biosynthesis.
Supporting Evidence
- TSA treatment downregulates 9 of 15 genes in the cholesterol biosynthesis pathway in F9 cells.
- In HepG2 cells, TSA treatment downregulates 11 of 15 pathway genes involved in cholesterol metabolism.
- The study found that Srebf2 downregulation may trigger the repression of cholesterol biosynthesis.
Takeaway
This research shows that a drug called TSA can help lower cholesterol by turning off certain genes that make cholesterol in the body.
Methodology
The study used microarray analysis and quantitative PCR to assess gene expression in F9 and HepG2 cell lines treated with TSA.
Limitations
The study only addresses transcript levels and further research is needed to evaluate protein expression.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website